Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05948826 · ClinicalTrials.gov registry record · Phase 1
First in Human Study of TORL-3-600 in Participants With Advanced Cancer
A Phase 1 study of Colorectal Cancer and Advanced Solid Tumor, sponsored by TORL Biotherapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
- 9
- Study locations
NCT05948826: Active Phase 1 study of Colorectal Cancer and Advanced Solid Tumor, sponsored by TORL Biotherapeutics.
NCT05948826 is a Phase 1 study of Colorectal Cancer and Advanced Solid Tumor that is active but no longer recruiting, run by TORL Biotherapeutics. The registered enrollment target is 70 participants, below the 1,544-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (95% lower). The trial reports 9 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05948826, a Phase 1 study of Colorectal Cancer and Advanced Solid Tumor, is active but no longer recruiting, sponsored by TORL Biotherapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
- 9
- Study locations
Study Summary
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-3-600 in patients with advanced cancer
Primary Outcome
Incidence and severity of adverse events, serious adverse events, according to NCI-CTCAE Version 5.0
Conditions Studied
Interventions
- DRUG TORL-3-600
Study Locations (9)
California
- Providence Medical Foundation - Fullerton
- UCLA - JCCC Clinical Research Unit - Los Angeles
Colorado
- Sarah Cannon Research Institute - Denver
Indiana
- Fort Wayne Medical Oncology and Hematology Inc. - Fort Wayne
Missouri
- Washington University School of Medicine-Siteman Cancer Center - St Louis
Tennessee
- Sarah Cannon Research Institute-Tennessee - Nashville
Texas
- Mary Crowley Cancer Research - Dallas
Ontario
- University Health Network, Princess Margaret Cancer Centre - Toronto
Quebec
- McGill University Health Centre - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2023-09-29 |
| Est. Completion | 2026-09-15 |
| Phase | Phase 1 |
What the registry record for NCT05948826 still lists
NCT05948826 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 1,544-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (95% lower).
The record links to 2 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 1 intervention - of which TORL-3-600 is the first listed.
NCT05948826 lists 9 locations in 8 states (California, Colorado, Indiana).
Frequently Asked Questions
What is clinical trial NCT05948826 about?
NCT05948826 is a clinical study titled "First in Human Study of TORL-3-600 in Participants With Advanced Cancer". This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-3-600 in patients with advanced cancer
What is the current status of trial NCT05948826?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2023-09-29. Estimated completion is 2026-09-15.
What conditions does trial NCT05948826 study?
This clinical trial studies the following conditions: Colorectal Cancer, Advanced Solid Tumor.
What interventions are being tested in trial NCT05948826?
The interventions under investigation include: TORL-3-600 (DRUG).
Who is sponsoring clinical trial NCT05948826?
This trial is sponsored by TORL Biotherapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05948826 being conducted?
This trial has 9 study locations across California, Colorado, Indiana, Missouri, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05948826's enrollment target sits among peer trials
70 244th of 381 higher than 134 of 381 other Colorectal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Colorectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RECRUITING · Phase 1
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI